Abstract
Second-line irinotecan regimens are efficacious in patients with advanced colorectal cancer who experience disease progression on first-line oxaliplatin-based chemotherapy. Bidard et al. investigated the impact of treatment with dose-dense irinotecan on improving survival in such patients and aimed to optimize the irinotecan combination chemotherapy platform.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call